Neuroimaging Predictors of Treatment Failure in Adult New-onset Epilepsy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-06-30

Study Completion Date

2014-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Epilepsy, defined as recurrent, unprovoked seizures, is a common condition, affecting 0.5-1% of the general population. People with uncontrolled epilepsy suffer poor health and increased mortality due to their condition. They frequently experience social stigma and are socioeconomically disadvantaged. It is therefore imperative to help them gain control of their seizures as quickly as possible. A wide range of antiepileptic drugs (AEDs) has become available to treat people with epilepsy. However, despite maximal therapy, approximately 20-40% show pharmacoresistance (PR) and thus continue to have seizures.

We do not understand why a significant proportion of people with epilepsy have PR. For any given patient presenting with a first unprovoked seizure, we are unable to predict PR at the time of presentation. At least 2 different AEDs must be tried at maximum doses for a year before we can diagnose PR. At this point, surgical therapies become an increasingly urgent consideration.

Retrospective magnetic resonance imaging (MRI) studies in the chronic stages of epilepsy have shown that patients with PR are more likely to have focal structural lesions in the brain, and in particular to have signs of damage to the hippocampi. For example, there are retrospective data suggesting that a decreased hippocampal N-acetylaspartate (NAA)/creatine ratio (measured by magnetic resonance spectroscopy \[MRS\]) and hippocampal atrophy (determined by hippocampal volumetry) correlate with PR. However, it is not clear whether these findings reflect the underlying pathophysiology of PR, or simply reflect the effects of chronic seizures and chronic drug treatment on the brain.

The First Seizure Clinic at the Halifax Infirmary represents a unique opportunity for prospective, longitudinal studies of patients who present with a first seizure or with newly diagnosed epilepsy. In these patients, advanced neuroimaging techniques at presentation might show changes that truly reflect the underlying pathophysiology of PR, rather than changes that develop as a consequence of prolonged seizures and drug treatment. Neuroimaging follow-up might help us to understand the pathophysiologic changes that accompany the evolution of PR. Ultimately, it is our hope to combine neuroimaging features and clinical features of patients with PR in a predictive model that would help us to predict PR at presentation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

MRI in Autosomal Dominant Partial Epilepsy With Auditory Features

NCT00072813

Epilepsies, Partial

COMPLETED

Multimodal Functional Neuroimaging in Epilepsy Patients

NCT02132507

Epilepsy

COMPLETED

Connectivity Analysis for Investigation of Auditory Impairment in Epilepsy

NCT01212068

Brain Mapping Intracranial Central Nervous System Disorder Epilepsy +2 more

TERMINATED

Evaluation, Pathogenesis, and Outcome of Subjects With or Suspected Traumatic Brain Injury

NCT01132937

Traumatic Brain Injury

COMPLETED

Neuroimaging Biomarker for Seizures

NCT03441867

Seizure Disorder Seizure Disorder, Post Traumatic Traumatic Brain Injury +5 more

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Epilepsy Seizures

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 17 years
* Newly diagnosed epilepsy or history of first unprovoked, witnessed seizure

Exclusion Criteria

* Lack of consent provoked seizure due to obvious
* Acute lesion on CT (e.g. stroke, hemorrhage
* Provoked seizure due to obvious, chronic lesion on CT (e.g. vascular malformation, tumour)
* Progressive brain disease (e.g. neoplastic, infectious, demyelinating diseases)
* History of epilepsy longer than 1 year at presentation to FSC
* History of AED treatment for more than 4 weeks
* Contraindication to MRI

Minimum Eligible Age

17 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No